Optimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects.

BMC research notes

Volumn 6, Issue , 2013, Pages 8-

  Allaire, Normand E ^a   Bushnell, Steven E ^b   Bienkowska, Jadwiga ^b   Brock, Graham ^b   Carulli, John ^b  

^a BIOGEN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; MACROGOL DERIVATIVE; MESSENGER RNA; POLYETHYLENE GLYCOL INTERFERON BETA 1A; POLYETHYLENE GLYCOL-INTERFERON BETA-1A;

ARTICLE; BLOOD; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; METHODOLOGY; REFERENCE VALUE;

GENE EXPRESSION PROFILING; HUMANS; INTERFERON-BETA; POLYETHYLENE GLYCOLS; REFERENCE VALUES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

MLCS; MLOWN;

EID: 84871810154     PISSN: None     EISSN: 17560500     Source Type: None    
DOI: 10.1186/1756-0500-6-8     Document Type: Article

References (0)